Internet Archive Scholar

Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013–2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors

Samantha Andreis, Monica Basso, Renzo Scaggiante, Mario Cruciani, Roberto Ferretto, Vinicio Manfrin, Sandro Panese, Maria Cristina Rossi, Ermenegildo Francavilla, Caterina Boldrin, Mario Alvarez, Federico Dal Bello (+7 others)
2017 Journal of Global Antimicrobial Resistance  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (472.0 kB)
https://web.archive.org/web/20190427230809/https://iris.uniroma1.it/retrieve/handle/11573/1165353/823479/Andreis_Drug-resistance_2017.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL. The file type is application/pdf.

A B S T R A C T Objectives: To characterize the prevalence of transmitted drug resistance mutations (TDRMs) by plasma analysis of 750 patients at the time of HIV diagnosis from January 1, 2013 to November 16, 2016 in the Veneto region (Italy), where all drugs included in the recommended first line therapies were prescribed, included integrase strand transfer inhibitors (InNSTI). Methods: TDRMs were defined according to the Stanford HIV database algorithm. Results: Subtype B was the most
more » ... t HIV clade (67.3%). A total of 92 patients (12.3%) were expected to be resistant to one drug at least, most with a single class mutation (60/68-88.2% in subtype B infected subjectsand 23/24-95.8% in non-B subjects) and affecting mainly NNRTIs. No significant differences were observed between the prevalence rates of TDRMs involving one or more drugs, except for the presence of E138A quite only in patients with B subtype and other NNRTI in subjects with non-B infection. The diagnosis of primary/recent infection was made in 73 patients (9.7%): they had almost only TDRMs involving a single class. Resistance to InSTI was studied in 484 subjects (53 with primary-recent infection), one patient had 143C in 2016, a total of thirteen 157Q mutations were detected (only one in primary/recent infection). Conclusions: Only one major InSTI-TDRM was identified but monitoring of TDRMs should continue in the light of continuing presence of NNRTI-related mutation amongst newly diagnosed subjects, sometime impacting also to modern NNRTI drugs recommended in first-line therapy.
doi:10.1016/j.jgar.2017.05.011 pmid:28732792 fatcat:zedduqhgf5anndqq2sgutyrilu
DOAJ
Citation

Samantha Andreis, Monica Basso, Renzo Scaggiante, Mario Cruciani, Roberto Ferretto, Vinicio Manfrin, Sandro Panese, Maria Cristina Rossi, Ermenegildo Francavilla, Caterina Boldrin, Mario Alvarez, Federico Dal Bello, Carlo Mengoli, Ombretta Turriziani, Loredana Sarmati, Guido Antonelli, Massimo Andreoni, Giorgio Palù, Saverio Giuseppe Parisi. "Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013–2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors." Journal of Global Antimicrobial Resistance (2017) 106-112